Cowen Reiterates Outperform on Ironwood Pharma (IRWD) Following IW-1973 Data

Cowen reiterated an Outperform rating and $20.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's presentation of additional data from its Phase IIa study testing IW-1973 in HFpEF.

IW-1973 led to improvements in insulin resistance as shown by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score decline by an average of 36% during the 14-day trial period, compared to 13% in patients taking a placebo.

For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.

Shares of Ironwood Pharmaceuticals closed at $19.34 yesterday.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'